83 related articles for article (PubMed ID: 16910582)
21. Treatment with prednisolone of hormone-refractory prostate cancer.
Fuse H; Nozaki T; Fujiuchi Y; Mizuno I; Nagakawa O; Okumura A
Arch Androl; 2006; 52(1):35-8. PubMed ID: 16338867
[TBL] [Abstract][Full Text] [Related]
22. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
[TBL] [Abstract][Full Text] [Related]
23. [Study on the safety of rapid infusion and the efficacy of incadronate against bone metastasis of breast cancer].
Oura S; Sakurai T; Yoshimura G; Tamaki T; Umemura T; Kokawa Y; Naito Y
Gan To Kagaku Ryoho; 1999 Oct; 26(11):1623-8. PubMed ID: 10553421
[TBL] [Abstract][Full Text] [Related]
24. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
[TBL] [Abstract][Full Text] [Related]
25. Health-related quality of life in patients with hormone refractory prostate cancer receiving gefitinib.
Curigliano G; Spitaleri G; De Cobelli O; Scardino E; Sbanotto A; de Braud F
Urol Int; 2009; 82(2):196-202. PubMed ID: 19322010
[TBL] [Abstract][Full Text] [Related]
26. Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer.
Turner SL; Gruenewald S; Spry N; Gebski V;
Br J Cancer; 2001 Feb; 84(3):297-302. PubMed ID: 11161391
[TBL] [Abstract][Full Text] [Related]
27. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America.
Gittelman M; Pommerville PJ; Persson BE; Jensen JK; Olesen TK;
J Urol; 2008 Nov; 180(5):1986-92. PubMed ID: 18801505
[TBL] [Abstract][Full Text] [Related]
28. Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer.
Numata K; Miura N; Azuma K; Karashima T; Kasahara K; Nakatsuzi H; Hashine K; Sumiyoshi Y
Hinyokika Kiyo; 2007 Feb; 53(2):99-104. PubMed ID: 17352158
[TBL] [Abstract][Full Text] [Related]
29. Survival after cytotoxic chemotherapy in patients with advanced hormone-resistant prostate cancer: a phase II study.
Stathopoulos GP; Koutantos J; Vaslamatzis MM; Athanasiadis A; Papadopoulos G; Labrodimou G; Stathopoulos J; Rigatos S
Oncol Rep; 2009 Aug; 22(2):345-8. PubMed ID: 19578775
[TBL] [Abstract][Full Text] [Related]
30. Cancer-related pain and quality of life in prostate cancer patients: assessment using the Functional Assessment of Prostate Cancer Therapy.
Fujimura T; Takahashi S; Kume H; Takeuchi T; ; Kitamura T; Homma Y
Int J Urol; 2009 May; 16(5):522-5. PubMed ID: 19383037
[TBL] [Abstract][Full Text] [Related]
31. [Breast cancer with osteoblastic bone metastasis treated successfully with bisphosphonate: a case report].
Oura S; Sakurai T; Yoshimura G; Tamaki T; Umemura T; Kokawa Y
Gan To Kagaku Ryoho; 1999 Oct; 26(11):1651-5. PubMed ID: 10553426
[TBL] [Abstract][Full Text] [Related]
32. Prednisone monotherapy in asymptomatic hormone refractory prostate cancer.
Heng DY; Chi KN
Can J Urol; 2006 Dec; 13(6):3335-9. PubMed ID: 17187697
[TBL] [Abstract][Full Text] [Related]
33. New agents in the therapy of hormone-refractory patients with prostate cancer.
Kantoff PW
Semin Oncol; 1995 Feb; 22(1 Suppl 1):32-4. PubMed ID: 7532323
[No Abstract] [Full Text] [Related]
34. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.
Ryan CJ; Weinberg V; Rosenberg J; Fong L; Lin A; Kim J; Small EJ
J Urol; 2007 Dec; 178(6):2372-6; discussion 2377. PubMed ID: 17936834
[TBL] [Abstract][Full Text] [Related]
35. A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer.
Morris MJ; Kelly WK; Slovin S; Ryan C; Eicher C; Heller G; Scher HI
J Urol; 2007 Dec; 178(6):2378-83; discussion 2383-4. PubMed ID: 17936848
[TBL] [Abstract][Full Text] [Related]
36. Feasibility of 21-day continuous infusion of epirubicin in hormone-refractory prostate cancer patients.
Berruti A; Mosca A; Bitossi R; Gorzegno G; Guercio S; Poggio M; Tampellini M; Porpiglia F; Ostellino O; Scarpa RM; Dogliotti L
Anticancer Res; 2005; 25(6C):4475-9. PubMed ID: 16334129
[TBL] [Abstract][Full Text] [Related]
37. Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life?
Cella D; Petrylak DP; Fishman M; Teigland C; Young J; Mulani P
Eur Urol; 2006 May; 49(5):781-9. PubMed ID: 16458417
[TBL] [Abstract][Full Text] [Related]
38. [Combined treatment for pain from bone metastases in patients with prostate cancer].
Ren X; Ying J; Yao D; Ye C; Jiang Y
Zhonghua Nan Ke Xue; 2004 Mar; 10(3):188-90. PubMed ID: 15080063
[TBL] [Abstract][Full Text] [Related]
39. Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study.
Nilsson S; Strang P; Ginman C; Zimmermann R; Edgren M; Nordström B; Ryberg M; Kälkner KM; Westlin JE
J Pain Symptom Manage; 2005 Apr; 29(4):352-7. PubMed ID: 15857738
[TBL] [Abstract][Full Text] [Related]
40. Complete regression of bone metastases on super bone scan, by low-dose cisplatin, UFT, diethylstilbestrol diphosphate, and dexamethasone in a patient with hormone-refractory prostate cancer.
Hoshi S; Ohyama C; Hagisawa S; Ono K; Satoh M; Saito S; Fukuzaki A; Arai Y
Int J Clin Oncol; 2003 Apr; 8(2):118-20. PubMed ID: 12720106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
